Anita Mangia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9445413/publications.pdf

Version: 2024-02-01

76 papers	2,202 citations	218381 26 h-index	253896 43 g-index
81 all docs	81 docs citations	81 times ranked	3683 citing authors

#	Article	IF	Citations
1	Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of Î²-tubulins. International Journal of Cancer, 2007, 120, 2078-2085.	2.3	132
2	The NHERF1 PDZ2 Domain Regulates PKAâ€“RhoAâ€“p38-mediated NHE1 Activation and Invasion in Breast Tumor Cells. Molecular Biology of the Cell, 2007, 18, 1768-1780.	0.9	121
3	Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. Translational Oncology, 2016, 9, 453-457.	1.7	113
4	Liver X Receptors Inhibit Proliferation of Human Colorectal Cancer Cells and Growth of Intestinal Tumors in Mice. Gastroenterology, 2013, 144, 1497-1507.e13.	0.6	85
5	High density of tryptaseâ€positive mast cells in human colorectal cancer: a poor prognostic factor related to proteaseâ€activated receptor 2 expression. Journal of Cellular and Molecular Medicine, 2013, 17, 1025-1037.	1.6	80
6	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt376.	3.0	77
7	3p Microsatellite Alterations in Exhaled Breath Condensate from Patients with Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 738-744.	2.5	75
8	Tissue remodelling in breast cancer: human mast cell tryptase as an initiator of myofibroblast differentiation. Histopathology, 2011, 58, 1096-1106.	1.6	75
9	Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer, 1989, 64, 1922-1927.	2.0	70
10	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biology and Therapy, 2016, 17, 400-406.	1.5	67
11	VEGF, HIF-1Î± Expression and MVD as an Angiogenic Network in Familial Breast Cancer. PLoS ONE, 2013, 8, e53070.	1.1	64
12	Biological role of NHERF1 protein expression in breast cancer. Histopathology, 2009, 55, 600-608.	1.6	54
13	Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. British Journal of Cancer, 2011, 104, 769-780.	2.9	52
14	HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer. Journal of Clinical Oncology, 2003, 21, 2708-2712.	0.8	48
15	Prognostic Relevance of Mitotic Activity in Patients with Node-Negative Breast Cancer. Modern Pathology, 2003, 16, 1067-1075.	2.9	46
16	Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers. Translational Oncology, 2018, 11, 825-835.	1.7	45
17	Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. International Journal of Cancer, 2004, 111, 252-258.	2.3	42
18	Overexpression of nuclear NHERF1 in advanced colorectal cancer: Association with hypoxic microenvironment and tumor invasive phenotype. Experimental and Molecular Pathology, 2012, 92, 296-303.	0.9	40

#	Article	IF	Citations
19	Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists. Journal of Molecular Diagnostics, 2008, 10, 527-536.	1.2	39
20	Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer. Journal of Clinical Oncology, 2001, 19, 3929-3937.	0.8	38
21	Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Modern Pathology, 2004, 17, 1038-1044.	2.9	37
22	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. Translational Oncology, 2019, 12, 585-595.	1.7	36
23	NHERF1/EBP50 in Breast Cancer: Clinical Perspectives. Breast Care, 2010, 5, 86-90.	0.8	33
24	Nuclear NHERF1 expression as a prognostic marker in breast cancer. Cell Death and Disease, 2013, 4, e904-e904.	2.7	32
25	Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumor Biology, 2016, 37, 6143-6153.	0.8	32
26	Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Molecular Cancer, 2009, 8, 29.	7.9	28
27	Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?. BMC Cancer, 2016, 16, 905.	1.1	25
28	Involvement of nuclear NHERF1 in colorectal cancer progression. Oncology Reports, 2012, 28, 889-894.	1.2	22
29	Irradiation-induced angiosarcoma and anti-angiogenic therapy: A therapeutic hope?. Experimental Cell Research, 2014, 321, 240-247.	1.2	21
30	SELDI-TOF serum proteomics and breast cancer: which perspective?. Expert Review of Proteomics, 2008, 5, 779-785.	1.3	20
31	CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen. International Journal of Molecular Sciences, 2014, 15, 15767-15777.	1.8	20
32	Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. European Journal of Cancer, 2015, 51, 1874-1881.	1.3	20
33	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. Breast Cancer Research and Treatment, 2016, 159, 79-86.	1.1	20
34	Na+/H+ exchanger regulatory factor 1 expression levels in blood and tissue predict breast tumour clinical behaviour. Histopathology, 2011, 58, 1086-1095.	1.6	19
35	NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1587.	1.3	19
36	Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and Western blot analyses. Oncology Reports, 2002, 9, 1127-32.	1.2	19

#	Article	IF	Citations
37	Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Research and Treatment, 2014, 144, 307-318.	1.1	18
38	NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings. Translational Oncology, 2018, 11, 374-390.	1.7	18
39	Fine Needle Aspiration Cytology: A Tool to Study NHERF1 Expression as a Potential Marker of Aggressiveness in Lung Cancer. Molecular Biotechnology, 2015, 57, 549-557.	1.3	16
40	NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 96.	3.5	16
41	Frizzled-10 and cancer progression: Is it a new prognostic marker?. Oncotarget, 2018, 9, 824-830.	0.8	16
42	Gene Copy Number Variation in Male Breast Cancer by aCGH. Analytical Cellular Pathology, 2010, 33, 113-119.	0.7	15
43	The prognostic value of the Na+/H+ exchanger regulatory factor 1 (NHERF1) protein in cancer. Cancer Biomarkers, 2014, 14, 177-184.	0.8	15
44	Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 705331.	1.3	15
45	Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer. Journal of Experimental and Clinical Cancer Research, 2010, 29, 125.	3.5	14
46	Human epidermal growth factor receptor 2, Na+/H+ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. Human Pathology, 2011, 42, 1589-1595.	1.1	14
47	Î²-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients. Oncotarget, 2016, 7, 67841-67850.	0.8	14
48	Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma. Oncotarget, 2018, 9, 22727-22740.	0.8	14
49	Old and new concepts in histopathological characterization of familial breast cancer. Annals of Oncology, 2011, 22, i24-i30.	0.6	13
50	FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics. Oncology Letters, 2016, 12, 3115-3122.	0.8	13
51	Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. International Journal of Cancer, 2016, 138, 110-120.	2.3	13
52	Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?. Cancers, 2019, 11, 1393.	1.7	13
53	NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients. Oncotarget, 2017, 8, 65730-65742.	0.8	13
54	Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?. Clinical Cancer Research, 2007, 13, 5988-5990.	3.2	12

#	Article	IF	Citations
55	Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers. Cancer Genetics and Cytogenetics, 2008, 182, 75-83.	1.0	12
56	Gene copy number variation in male breast cancer by aCGH. Cellular Oncology (Dordrecht), 2011, 34, 467-473.	2.1	12
57	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. Cancer Biology and Therapy, 2015, 16, 1140-1147.	1.5	12
58	Independent Negative Prognostic Role of TCF1 Expression within the Wnt/Î²-Catenin Signaling Pathway in Primary Breast Cancer Patients. Cancers, 2019, 11, 1035.	1.7	12
59	Predictability of Monthly and Yearly Rhythms of Breast Cancer Features. Breast Cancer Research and Treatment, 2001, 67, 41-49.	1.1	10
60	Biomarkers for Early Cancer Detection â€“ Methodological Aspects. Breast Care, 2010, 5, 62-65.	0.8	10
61	Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clinical Biochemistry, 2011, 44, 936-940.	0.8	10
62	VEGF and TWIST1 in a 16â€biomarker immunoprofile useful for prognosis of breast cancer patients. International Journal of Cancer, 2017, 141, 1901-1911.	2.3	10
63	Touch Imprint Cytology in Tumor Tissue Banks for the Confirmation of Neoplastic Cellularity and for DNA Extraction. Archives of Pathology and Laboratory Medicine, 2008, 132, 974-978.	1.2	10
64	H pyloristatus and angiogenesis factors in human gastric carcinoma. World Journal of Gastroenterology, 2006, 12, 5465.	1.4	9
65	Cytosolic Levels of Estrogen-Regulated pS2 Protein in Breast Cancer: Correlation with Tumor Proliferative Activity. Tumor Biology, 1993, 14, 30-37.	0.8	8
66	Cytosol cathepsin-D content and proliferative activity of human breast cancer. Breast Cancer Research and Treatment, 1992, 23, 63-70.	1.1	7
67	Sister chromatid exchange: A possible approach to characterize familial breast cancer patients. Oncology Reports, 2015, 33, 930-934.	1.2	7
68	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: apost hocanalysis of the IBIS 3 trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591988899.	1.4	7
69	Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients. Translational Oncology, 2020, 13, 186-192.	1.7	6
70	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. International Journal of Biological Markers, 2009, 24, 119-129.	0.7	6
71	Mammographic Aspect, Cell Kinetics and Hormone Receptor Status of Operable Breast Cancer. Oncology, 1993, 50, 104-109.	0.9	5
72	Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis. Clinical and Experimental Medicine, 2001, 1, 127-132.	1.9	5

#	Article	IF	Citations
73	Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. Oncology Reports, 2010, 23, 1641-5.	1.2	5
74	Immunoprofile from tissue microarrays to stratify familial breast cancer patients. Oncotarget, 2015, 6, 27865-27879.	0.8	5
75	Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype. Oncotarget, 2017, 8, 87782-87794.	0.8	4
76	Research Trends for Early Cancer Biomarker Detection in Italy: An Integrated Program in Oncology (PIO) Survey. Tumori, 2010, 96, 721-725.	0.6	0